Bruno Strigini - Novartis CEO

NVS Stock  USD 95.88  0.61  0.64%   

CEO

Mr. Bruno Strigini resigned as Chief Executive Officer of Novartis Oncology and Member of the Executive Committee of Novartis Inc. effective as of December 31, 2017, a position he has held since July 1, 2016. He joined Novartis in 2014 as President of Oncology. Prior to Novartis, he was President of MSD for Europe and Canada . He previously worked at ScheringPlough, UCB Celltech and SmithKline Beecham, and his roles included president of international operations, president of Japan and AsiaPacific, head of global marketing and business development, and managing director positions. since 2016.
Tenure 8 years
Address Lichtstrasse 35, Basel, Switzerland, 4056
Phone41 61 324 1111
Webhttps://www.novartis.com

Novartis Management Efficiency

The company has Return on Asset of 0.0727 % which means that on every $100 spent on assets, it made $0.0727 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1615 %, implying that it generated $0.1615 on every 100 dollars invested. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novartis' Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 0.33 in 2024, whereas Return On Assets are likely to drop 0.11 in 2024. At this time, Novartis' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 73.2 B in 2024, whereas Total Current Assets are likely to drop slightly above 29.9 B in 2024.
The company has 26.35 B in debt with debt to equity (D/E) ratio of 0.47, which is OK given its current industry classification. Novartis AG ADR has a current ratio of 1.28, demonstrating that it may not be capable to disburse its financial commitments when the payables are due. Debt can assist Novartis until it has trouble settling it off, either with new capital or with free cash flow. So, Novartis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novartis AG ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novartis to invest in growth at high rates of return. When we think about Novartis' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 8 records

CEO Age

Eric MBASeres Therapeutics
48
William SiboldMadrigal Pharmaceuticals
58
Chen SchorMadrigal Pharmaceuticals
41
Shawn IadonatoKineta Inc
54
Manuel MDMustang Bio
70
Geoffrey RotsteinEquillium
N/A
Frans Blom23Andme Holding Co
40
Michael McMullenAgilent Technologies
63
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 108000 people. Novartis AG ADR (NVS) is traded on New York Stock Exchange in USA. It is located in Lichtstrasse 35, Basel, Switzerland, 4056 and employs 76,057 people. Novartis is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Novartis AG ADR Leadership Team

Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charlotte Wieser, Corporate Secretary
Ton Buechner, Non-Executive Independent Director
Robert PharmD, Chief Officer
Verena Briner, Non-Executive Independent Member of the Board
Karen Hale, Chief Legal Officer, Member of the Executive Board
Chris Ilsley, President CEO
Steven Baert, Chief People & Organization Officer, Member of the Executive Committee
Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee
Richard Francis, Member of the Executive Committee and Division Head, Sandoz
Daniel Vasella, Honorary Chairman of the Board
Pierre Landolt, Member of the Board of Directors
Elizabeth Doherty, Non-Executive Independent Director
Erwin Vanhaecke, Head Novartis Group Quality
Victor Bulto, President Innovative Medicines US, Member of the Executive Board
Fiona Marshall, President Research
Elizabeth Barrett, CEO, Novartis Oncology
Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Charlotte PamerWieser, Corporate Secretary
Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel
Shreeram MD, President Officer
Samir Shah, Global Head Investor Relations
David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals
Srikant Datar, Non-Executive Independent Director
MarieFrance Tschudin, President, Innovative Medicines International and Chief Commercial Officer, Member of the Executive Board
Samir MD, Global Relations
Simon Moroney, Non-Executive Independent Director
Francesco Balestrieri, Chief Executive Officer of Sandoz, Member of the Executive Committee
Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee
Paul Penepent, Head Accounting
Joerg Reinhardt, Independent Non-Executive Chairman of the Board
Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
Brian McNamara, Member of the Management Board, Division Head, Novartis OTC
Andrews C, Non-Executive Independent Director
Michele Galen, Head Communications
Charles Sawyers, Non-Executive Independent Member of the Board
Etienne Jousseaume, Cell Access
John Tsai, Head of Global Drug Development and Chief Medical Officer, Member of the Executive Committee
Dimitri Azar, Non-Executive Independent Director
Frans Houten, Non-Executive Independent Director
Nancy Andrews, Non-Executive Independent Director
Susanne Schaffert, President of Novartis Oncology, Member of the Executive Committee
Enrico Vanni, Lead Independent Non-Executive Vice Chairman of the Board
Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee
Robert Weltevreden, Head of Customer and Technology Solutions, Member of the Executive Committee
Patrick MD, President International
Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland
Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Alex Krauer, Honorary Chairman of the Board
Michael Ball, CEO of Alcon, Member of the Executive Committee
Jeffrey George, Member of the Executive Committee and Division Head, Sandoz
Patrice Bula, Non-Executive Independent Director
Linda MD, Global Development
Peter Kornicker, Chief Compliance Officer
Andreas Planta, Non-Executive Independent Director
Joseph Jimenez, CEO, Member of the Executive Committee
Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director
William Winters, Non-Executive Independent Member of the Board
Ann Fudge, Non-Executive Independent Director
Robert Kowalski, Chief People and Organization Officer
George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility
Paul Arkel, Head of Corporate Strategy and External Affairs
James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee
Aharon Gal, Chief Officer
Vasant MD, Chief Officer
Felix Ehrat, General Counsel and General Counsel of Novartis International Ag
Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics
Bridgette Heller, Non-Executive Independent Director

Novartis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Fundamental Analysis
View fundamental data based on most recent published financial statements
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
CEOs Directory
Screen CEOs from public companies around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
4.987
Dividend Share
3.919
Earnings Share
4.1
Revenue Per Share
22.467
Quarterly Revenue Growth
0.074
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.